作者: Joe Anderson , Elshaboury
DOI: 10.2147/PPA.S30949
关键词: Nasal congestion 、 Peripheral edema 、 Progressive disease 、 Sinusitis 、 Pharmacology 、 Clinical trial 、 Survival rate 、 Endothelin receptor antagonist 、 Ambrisentan 、 Medicine 、 Internal medicine
摘要: Pulmonary arterial hypertension (PAH) is a progressive disease of the pulmonary vasculature that associated with severe functional impairment and poor prognosis. Ambrisentan selective endothelin type A receptor antagonist approved for treatment patients PAH World Health Organization group 1. The efficacy safety ambrisentan has been evaluated in ARIES series (Ambrisentan Treatment Arterial Hypertension, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Efficacy Studies), which established its use as both monotherapy or conjunction other therapies. Specifically, effective at increasing exercise tolerance, decreasing risk class deterioration, prolonging time to clinical worsening. Further, favorable effect on mortality, an 88% patient survival rate after two years therapy compared 61% estimated by National Institute Registry. generally well tolerated all groups, main side effects peripheral edema, sinusitis, flushing, nasal congestion considered be mild moderate nature. several qualities potentially make it more acceptable patients, including once-daily administration, limited adverse drug reactions drug-drug interactions, minimal liver enzyme elevation. Because potential teratogenicity ambrisentan, only available through distribution program, ie, LEAP (the Letairis Education Access Program). Ongoing trials will help clarify role PAH.